Novartis wagers billions of dollars on PTC Huntington’s drug

Novartis could pay close to $3 billion for brain drugs developed by PTC Therapeutics, per a deal announced Monday.

At the center of the deal is an experimental medicine, PTC518, which is currently being tested as a potential treatment for Huntington’s disease in a roughly 250-person clinical trial.